Vabysmo Hopes To Ride New Coverage In China, Data To Expand In Asia

NRDL Listing For Three Indications

 
• By Dexter Jie Yan

Roche's blockbuster ophthalmic drug set for China reimbursement list inclusion in three indications and shows positive interim results in PCV.

Asia ophthalmology
On 28 November, Roche announced Vabysmo’s inclusion in China’s National Reimbursement Drug List (NRDL) from 2025 to 2026. (Shutterstock)

More from China

More from Scrip